Table Graph
      published meta-analysis   sensitivity analysis   studies

dexamethasone in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsJamaati, 2021 1.19 [0.38; 3.72] 1.19[0.38; 3.72]Jamaati, 202110%50NAnot evaluable deathsdetailed resultsCODEX (Tomazini), 2020 0.97 [0.72; 1.31] DEXA-COVID19, 2020 2.00 [0.21; 18.87] Jamaati, 2021 1.19 [0.38; 3.72] 0.99[0.75; 1.32]CODEX (Tomazini), 2020, DEXA-COVID19, 2020, Jamaati, 202130%368moderatenot evaluable clinical deteriorationdetailed resultsCODEX (Tomazini), 2020 0.66 [0.43; 1.02] 0.66[0.43; 1.02]CODEX (Tomazini), 202010%299NAnot evaluable mechanical ventilationdetailed resultsJamaati, 2021 1.38 [0.45; 4.20] 1.38[0.45; 4.20]Jamaati, 202110%50NAnot evaluable radiologic improvement (14-day)detailed resultsJamaati, 2021 4.89 [1.15; 20.79] 4.89[1.15; 20.79]Jamaati, 202110%50NAnot evaluable serious adverse eventsdetailed resultsCODEX (Tomazini), 2020 0.53 [0.17; 1.62] 0.53[0.17; 1.62]CODEX (Tomazini), 202010%299NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-04-26 23:54 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 666,1149,1150 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons